• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The bicyclic intermediate structure provides insights into the desuccinylation mechanism of human sirtuin 5 (SIRT5).双环中间体结构为深入了解人源 SIRT5(去琥珀酰化酶 5)的去琥珀酰化机制提供了线索。
J Biol Chem. 2012 Aug 17;287(34):28307-14. doi: 10.1074/jbc.M112.384511. Epub 2012 Jul 5.
2
Structural insights into the molecular mechanism underlying Sirt5-catalyzed desuccinylation of histone peptides.解析组学揭示 Sirt5 催化组蛋白肽去琥珀酰化的分子机制。
Biochem J. 2019 Jan 18;476(2):211-223. doi: 10.1042/BCJ20180745.
3
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase.Sirt5 是一种 NAD 依赖性蛋白赖氨酸脱琥珀酰酶和去琥珀酰酶。
Science. 2011 Nov 11;334(6057):806-9. doi: 10.1126/science.1207861.
4
Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors.Sirtuin 5:结构综述、已知抑制剂及开发新型抑制剂的线索。
Sci China Life Sci. 2017 Mar;60(3):249-256. doi: 10.1007/s11427-016-0060-7. Epub 2016 Nov 17.
5
Chemical probing of the human sirtuin 5 active site reveals its substrate acyl specificity and peptide-based inhibitors.靶向人类 SIRT5 活性位点的化学探测揭示了其底物酰基特异性和基于肽的抑制剂。
Angew Chem Int Ed Engl. 2014 Sep 26;53(40):10728-32. doi: 10.1002/anie.201402679. Epub 2014 Aug 11.
6
Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.苏拉明对人NAD⁺依赖性脱乙酰酶SIRT5的抑制作用的结构基础
Structure. 2007 Mar;15(3):377-89. doi: 10.1016/j.str.2007.02.002.
7
Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition.Sirt5 的去酰化酶活性对烟酰胺的抑制作用表现出不同的敏感性。
PLoS One. 2012;7(9):e45098. doi: 10.1371/journal.pone.0045098. Epub 2012 Sep 19.
8
Overview of SIRT5 as a potential therapeutic target: Structure, function and inhibitors.SIRT5作为潜在治疗靶点的概述:结构、功能及抑制剂
Eur J Med Chem. 2022 Jun 5;236:114363. doi: 10.1016/j.ejmech.2022.114363. Epub 2022 Apr 8.
9
Synthesis of carba-NAD and the structures of its ternary complexes with SIRT3 and SIRT5.卡巴 NAD 的合成及其与 SIRT3 和 SIRT5 的三元配合物的结构。
J Org Chem. 2012 Sep 7;77(17):7319-29. doi: 10.1021/jo301067e. Epub 2012 Aug 17.
10
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.NAD(+)依赖性蛋白质去琥珀酰化酶和去丙二酰化酶Sirt5的抑制剂。
ACS Med Chem Lett. 2012 Oct 6;3(12):1050-3. doi: 10.1021/ml3002709. eCollection 2012 Dec 13.

引用本文的文献

1
SIRT5: a potential target for discovering bioactive natural products.沉默调节蛋白5:发现生物活性天然产物的潜在靶点。
J Nat Med. 2025 May;79(3):441-464. doi: 10.1007/s11418-024-01871-6. Epub 2025 Feb 20.
2
Structural basis of SIRT7 nucleosome engagement and substrate specificity.SIRT7与核小体结合及底物特异性的结构基础。
Nat Commun. 2025 Feb 4;16(1):1328. doi: 10.1038/s41467-025-56529-y.
3
Inhibition of Sirtuin Deacylase Activity by Peroxynitrite.过氧亚硝酸盐抑制 Sirtuin 脱酰酶活性。
Biochemistry. 2024 Oct 1;63(19):2463-2476. doi: 10.1021/acs.biochem.4c00257. Epub 2024 Sep 10.
4
Current Trends in Sirtuin Activator and Inhibitor Development.当前 Sirtuin 激活剂和抑制剂研发的趋势。
Molecules. 2024 Mar 6;29(5):1185. doi: 10.3390/molecules29051185.
5
Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection.SIRT5 在代谢、癌症和 SARS-CoV-2 感染中的新兴作用。
Cells. 2023 Mar 9;12(6):852. doi: 10.3390/cells12060852.
6
Structural Basis of Sirtuin 6-Catalyzed Nucleosome Deacetylation.Sirtuin 6 催化核小体去乙酰化的结构基础。
J Am Chem Soc. 2023 Mar 29;145(12):6811-6822. doi: 10.1021/jacs.2c13512. Epub 2023 Mar 17.
7
Why Is Longevity Still a Scientific Mystery? Sirtuins-Past, Present and Future.为什么长寿仍是一个科学之谜?Sirtuins——过去、现在和未来。
Int J Mol Sci. 2022 Dec 31;24(1):728. doi: 10.3390/ijms24010728.
8
Virtual Screening in the Identification of Sirtuins' Activity Modulators.虚拟筛选鉴定 Sirtuins 活性调节剂。
Molecules. 2022 Sep 1;27(17):5641. doi: 10.3390/molecules27175641.
9
Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5.蛋白赖氨酸去乙酰化酶 Sirtuin 5 的治疗潜力和活性调节。
J Med Chem. 2022 Jul 28;65(14):9580-9606. doi: 10.1021/acs.jmedchem.2c00687. Epub 2022 Jul 8.
10
Mechanism-based inhibitors of SIRT2: structure-activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration.基于机制的SIRT2抑制剂:构效关系、X射线晶体结构、靶点结合、α-微管蛋白乙酰化调控及对乳腺癌细胞迁移的抑制作用
RSC Chem Biol. 2021 Jan 14;2(2):612-626. doi: 10.1039/d0cb00036a. eCollection 2021 Apr 1.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Thiosuccinyl peptides as Sirt5-specific inhibitors.硫代琥珀酰肽作为 Sirt5 的特异性抑制剂。
J Am Chem Soc. 2012 Feb 1;134(4):1922-5. doi: 10.1021/ja2090417. Epub 2012 Jan 20.
3
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase.Sirt5 是一种 NAD 依赖性蛋白赖氨酸脱琥珀酰酶和去琥珀酰酶。
Science. 2011 Nov 11;334(6057):806-9. doi: 10.1126/science.1207861.
4
The first identification of lysine malonylation substrates and its regulatory enzyme.赖氨酸丙二酰化修饰底物及其调控酶的首次鉴定。
Mol Cell Proteomics. 2011 Dec;10(12):M111.012658. doi: 10.1074/mcp.M111.012658. Epub 2011 Sep 9.
5
Identification of lysine succinylation as a new post-translational modification.鉴定赖氨酸琥珀酰化作为一种新的翻译后修饰。
Nat Chem Biol. 2011 Jan;7(1):58-63. doi: 10.1038/nchembio.495. Epub 2010 Dec 12.
6
Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity.神经 Sirtuin 6(Sirt6)缺失会减弱躯体生长并导致肥胖。
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21790-4. doi: 10.1073/pnas.1016306107. Epub 2010 Nov 22.
7
Crystal structures of human SIRT3 displaying substrate-induced conformational changes.显示底物诱导构象变化的人源SIRT3晶体结构。
J Biol Chem. 2009 Sep 4;284(36):24394-405. doi: 10.1074/jbc.M109.014928. Epub 2009 Jun 16.
8
SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle.SIRT5使氨甲酰磷酸合成酶1去乙酰化并调节尿素循环。
Cell. 2009 May 1;137(3):560-70. doi: 10.1016/j.cell.2009.02.026.
9
Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD.利用烟酰胺腺嘌呤二核苷酸(NAD)类似物和32P-NAD研究沉默调节蛋白的ADP核糖基转移酶活性。
Biochemistry. 2009 Apr 7;48(13):2878-90. doi: 10.1021/bi802093g.
10
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau.烟酰胺通过一种涉及抑制沉默调节蛋白和选择性降低苏氨酸231磷酸化tau蛋白的机制恢复阿尔茨海默病转基因小鼠的认知能力。
J Neurosci. 2008 Nov 5;28(45):11500-10. doi: 10.1523/JNEUROSCI.3203-08.2008.

双环中间体结构为深入了解人源 SIRT5(去琥珀酰化酶 5)的去琥珀酰化机制提供了线索。

The bicyclic intermediate structure provides insights into the desuccinylation mechanism of human sirtuin 5 (SIRT5).

机构信息

MacCHESS, Cornell High Energy Synchrotron Source, Cornell University, Ithaca, New York 14853, USA.

出版信息

J Biol Chem. 2012 Aug 17;287(34):28307-14. doi: 10.1074/jbc.M112.384511. Epub 2012 Jul 5.

DOI:10.1074/jbc.M112.384511
PMID:22767592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3436533/
Abstract

Sirtuins are pivotal regulators in various cellular processes, including transcription, DNA repair, genome stability, and energy metabolism. Their functions have been generally attributed to NAD-dependent deacetylase activity. However, human SIRT5 (sirtuin 5), which has been reported to exhibit little deacetylase activity, was recently identified as an NAD-dependent demalonylase and desuccinylase. Biochemical studies suggested that the mechanism of SIRT5-catalyzed demalonylation and desuccinylation is similar to that of deacetylation catalyzed by other sirtuins. Previously, we solved the crystal structure of a SIRT5-succinyl-lysine peptide-NAD complex. Here, we present two more structures: a binary complex of SIRT5 with an H3K9 succinyl peptide and a binary complex of SIRT5 with a bicyclic intermediate obtained by incubating SIRT5-H3K9 thiosuccinyl peptide co-crystals with NAD. To our knowledge, this represents the first bicyclic intermediate for a sirtuin-catalyzed deacylation reaction that has been captured in a crystal structure, thus providing unique insights into the reaction mechanism. The structural information should benefit the design of specific inhibitors for SIRT5 and help in exploring the therapeutic potential of targeting sirtuins for treating human diseases.

摘要

Sirtuins 是各种细胞过程中的关键调节因子,包括转录、DNA 修复、基因组稳定性和能量代谢。它们的功能通常归因于 NAD 依赖性脱乙酰酶活性。然而,最近被鉴定为 NAD 依赖性脱戊二酰基酶和脱琥珀酰基酶的人类 SIRT5(sirtuin 5)几乎没有脱乙酰酶活性。生化研究表明,SIRT5 催化脱戊二酰基和脱琥珀酰基的机制类似于其他 sirtuins 催化的脱乙酰化。此前,我们解决了 SIRT5-琥珀酰基-赖氨酸肽-NAD 复合物的晶体结构。在这里,我们呈现了另外两个结构:SIRT5 与 H3K9 琥珀酰化肽的二元复合物,以及 SIRT5 与通过用 NAD 孵育 SIRT5-H3K9 硫代琥珀酰肽共晶获得的双环中间体的二元复合物。据我们所知,这代表了第一个在晶体结构中捕获的 sirtuin 催化脱酰基反应的双环中间体,从而为反应机制提供了独特的见解。这些结构信息应该有助于设计针对 SIRT5 的特异性抑制剂,并有助于探索针对人类疾病的靶向 sirtuins 的治疗潜力。